Lydia Kerkerian-Le Goff

Lydia Kerkerian-Le Goff

Auto-generated profile, based on publicly available information

Lydia Kerkerian-Le Goff

Aix-Marseille Univ, CNRS, IBDM, Marseille, France

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2004 in Clinical Neurophysiology
Verified
Journal Article
Closed access
CMCameron C McIntyre
Cameron C McIntyre
MSMarc Savasta
Marc Savasta
LGLydia Kerkerian-Le Goff
Lydia Kerkerian-Le Goff
JVJerrold L Vitek
Jerrold L Vitek

1 October 2001 in Neurobiology of Disease
Verified
Journal Article
Closed access
JLJean-Charles Liévens
Jean-Charles Liévens
BWB. Woodman
B. Woodman
AMA. Mahal
A. Mahal
OSO. Spasic-Boscovic
O. Spasic-Boscovic
DSD. Samuel
D. Samuel
GBG.P. Bates
G.P. Bates

31 August 2016 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SZSamira Ztaou
Samira Ztaou
NMNicolas Maurice
Nicolas Maurice
JCJeremy Camon
Jeremy Camon
GGGaëlle Guiraudie-Capraz
Gaëlle Guiraudie-Capraz
LGLydia Kerkerian-Le Goff
Lydia Kerkerian-Le Goff
MAMarianne Amalric
Marianne Amalric
Over the last decade, striatal cholinergic interneurons (ChIs) have reemerged as key actors in the pathophysiology of basal-ganglia-related movement disorders. However, the mechanisms involved are still unclear. In this study, we address the role of ChI activity in the expression of parkinsonian-like motor deficits in a unilateral nigrostriatal 6-hydroxydopamine (6-OHDA) lesion model using optogenetic and pharmacological approaches. Dorsal striatal photoinhibition of ChIs in lesioned ChATcre/cre mice expressing halorhodopsin in ChIs reduces akinesia, bradykinesia, and sensorimotor neglect. Muscarinic acetylcholine receptor (mAChR) blockade by scopolamine produces similar anti-parkinsonian effects. To decipher which of the mAChR subtypes provides these beneficial effects, systemic and intrastriatal administration of the selective M1 and M4 mAChR antagonists telenzepine and tropicamide, respectively, were tested in the same model of Parkinson's disease. The two compounds alleviate 6-OHDA lesion-induced motor deficits. Telenzepine produces its beneficial effects by blocking postsynaptic M1 mAChRs expressed on medium spiny neurons (MSNs) at the origin of the indirect striatopallidal and direct striatonigral pathways. The anti-parkinsonian effects of tropicamide were almost completely abolished in mutant lesioned mice that lack M4 mAChRs specifically in dopamine D1-receptor-expressing neurons, suggesting that postsynaptic M4 mAChRs expressed on direct MSNs mediate the antiakinetic action of tropicamide. The present results show that altered cholinergic transmission via M1 and M4 mAChRs of the dorsal striatum plays a pivotal role in the occurrence of motor symptoms in Parkinson's disease. SIGNIFICANCE STATEMENT The striatum, where dopaminergic and cholinergic systems interact, is the pivotal structure of basal ganglia involved in pathophysiological changes underlying Parkinson's disease. Here, using optogenetic and pharmacological approaches, we investigated the involvement of striatal cholinergic interneurons (ChIs) and muscarinic receptor subtypes (mAChRs) in the occurrence of a wide range of motor deficits such as akinesia, bradykinesia, motor coordination, and sensorimotor neglect after unilateral nigrostriatal 6-hydroxydopamine lesion in mice. Our results show that photoinhibition of ChIs in the dorsal striatum and pharmacological blockade of muscarinic receptors, specifically postsynaptic M1 and M4 mAChRs, alleviate lesion-induced motor deficits. The present study points to these receptor subtypes as potential targets for the symptomatic treatment of parkinsonian-like motor symptoms.

1 July 2009 in Neuropsychopharmacology
Verified
Journal Article
Closed access
ASAmélie Soumier
Amélie Soumier
MBMounira Banasr
Mounira Banasr
SLSylviane Lortet
Sylviane Lortet
FMFrédérique Masmejean
Frédérique Masmejean
NBNathalie Bernard
Nathalie Bernard
ADAnnie Daszuta
Annie Daszuta

12 June 2009 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
CBCorinne Beurrier
Corinne Beurrier
SLSebastien Lopez
Sebastien Lopez
DRDelphine Révy
Delphine Révy
CSChelliah Selvam
Chelliah Selvam
CGCyril Goudet
Cyril Goudet
MAMarianne Amalric
Marianne Amalric
Developing nondopaminergic palliative treatments for Parkinson's disease represents a major challenge to avoid the debilitating side effects produced by l ‐DOPA therapy. Increasing interest is addressed to the selective targeting of group III metabotropic glutamate (mGlu) receptors that inhibit transmitter release at presumably overactive synapses in the basal ganglia. Here we characterize the functional action of a new orthosteric group III mGlu agonist, LSP1–2111, with a preferential affinity for mGlu4 receptor. In mouse brain slices, LSP1– 2111 inhibits striatopallidal GABAergic transmission by selectively activating the mGlu4 receptor but has no effect at a synapse modulated solely by the mGlu7 and mGlu8 receptors. Intrapallidal LSP1–2111 infusion reverses the akinesia produced by nigrostriatal dopamine depletion in a reaction time task, whereas an mGlu8–receptor agonist has no effect. Finally, systemic administration of LSP1–2111 counteracts haloperidol‐induced catalepsy, opening promising perspectives for the development of antiparkinsonian therapeutic strategies focused on orthosteric mGlu4–receptor agonists.—Beurrier, C., Lopez, S., Révy, D., Selvam, C., Goudet, C., Lhérondel, M., Gubellini, P., Kerkerian‐LeGoff, L., Acher, F., Pin, J.‐P., Amalric, M. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J . 23, 3619–3628 (2009). www.fasebj.org

1 October 2015 in Cell Reports
Verified
Journal Article
Open access
NMNicolas Maurice
Nicolas Maurice
MLMartine Liberge
Martine Liberge
FJFlorence Jaouen
Florence Jaouen
SZSamira Ztaou
Samira Ztaou
MHMarwa Hanini
Marwa Hanini
CBCorinne Beurrier
Corinne Beurrier
Despite evidence showing that anticholinergic drugs are of clinical relevance in Parkinson's disease (PD), the causal role of striatal cholinergic interneurons (CINs) in PD pathophysiology remains elusive. Here, we show that optogenetic inhibition of CINs alleviates motor deficits in PD mouse models, providing direct demonstration for their implication in parkinsonian motor dysfunctions. As neural correlates, CIN inhibition in parkinsonian mice differentially impacts the excitability of striatal D1 and D2 medium spiny neurons, normalizes pathological bursting activity in the main basal ganglia output structure, and increases the functional weight of the direct striatonigral pathway in cortical information processing. By contrast, CIN inhibition in non-lesioned mice does not affect locomotor activity, equally modulates medium spiny neuron excitability, and does not modify spontaneous or cortically driven activity in the basal ganglia output, suggesting that the role of these interneurons in motor function is highly dependent on dopamine tone.